Offspring affected with in utero Zika virus infection retain molecular footprints in the bone marrow and blood cells

Emerg Microbes Infect. 2023 Dec;12(1):2147021. doi: 10.1080/22221751.2022.2147021.

Abstract

Congenital virus infections, for example cytomegalovirus and rubella virus infections, commonly affect the central nervous and hematological systems in fetuses and offspring. However, interactions between emerging congenital Zika virus and hematological system-bone marrow and blood-in fetuses and offspring are mainly unknown. Our overall goal was to determine whether silent in utero Zika virus infection can cause functional and molecular footprints in the bone marrow and blood of fetuses and offspring. We specifically focused on silent fetal infection because delayed health complications in initially asymptomatic offspring were previously demonstrated in animal and human studies. Using a well-established porcine model for Zika virus infection and a set of cellular and molecular experimental tools, we showed that silent in utero infection causes multi-organ inflammation in fetuses and local inflammation in the fetal bone marrow. In utero infection also caused footprints in the offspring bone marrow and PBMCs. These findings should be considered in a broader clinical context because of growing concerns about health sequelae in cohorts of children affected with congenital Zika virus infection in the Americas. Understanding virus-induced molecular mechanisms of immune activation and inflammation in fetuses may provide targets for early in utero interventions. Also, identifying early biomarkers of in utero-acquired immunopathology in offspring may help to alleviate long-term sequelae.

Keywords: RNA-seq; Zika virus; bone marrow; fetus; hematopoietic stem cells; kinome; offspring; pig.

MeSH terms

  • Animals
  • Blood Cells / pathology
  • Bone Marrow
  • Child
  • Female
  • Humans
  • Inflammation
  • Swine
  • Zika Virus Infection*
  • Zika Virus* / genetics

Grants and funding

This work was supported by grants to UK from New Frontier in Research Fund (NFRF) #421586 and Canadian Institutes of Health Research (CIHR) Project Grant #424307. DU received Scholarship from the School of Public Health, University of Saskatchewan. VIDO receives operational funding from the Government of Saskatchewan through Innovation Saskatchewan and the Ministry of Agriculture and from the Canada Foundation for Innovation through the Major Science Initiatives for its CL3 facility (InterVac). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.